Eradivir's EV25 therapeutic reduces advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies

A research article shows that Eradivir's patent-pending antiviral therapeutic called EV25 reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.

A research article shows that Eradivir's patent-pending antiviral therapeutic called EV25 reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.

Read more https://www.sciencedaily.com/releases/2024/11/241119132323.htm